HAEGARDA Registration and Sign Up Information | haegarda

^*	In a later analysis of 63 patients followed over an average of 1.5 years, the median time to first attack was 224 days. Although these results support the primary findings, the study was not designed in advance to measure the median days to first attack.
^†	In the clinical trial, the median reduction in number of attacks in people receiving HAEGARDA 60 IU/kg vs placebo. You should always have HAE rescue medication available at all times in case of a breakthrough attack.
	Please see Important Safety Information below. In clinical studies, the most common side effects reported with HAEGARDA were injection-site reactions (pain, redness, swelling); hypersensitivity (itching and rash), dizziness, and nasal symptoms, including stuffy or runny nose and sneezing.

HAE attacks don’t have to interrupt your life. Discover the difference HAEGARDA can make.

HAEGARDA is the HAE therapy that reduced attacks by 95%.^‡ As a preventive therapy, HAEGARDA can effectively reduce the number of HAE attacks you experience.
^‡Median reduction in number of attacks vs placebo.

Real stories from HAEGARDA patients

See stories from others who have HAE and connect with a HAEGARDA Advocate^§, a person just like you who knows what you are going through.

^§Advocates are not healthcare providers or medical experts and are compensated for their participation. For medical questions, you should contact your physician.

Start the discussion off right

Be prepared and ask the right questions. Get the Doctor Discussion Guide to help you get started.

GET DOCTOR DISCUSSION GUIDE >

Personalized support from the start

Committed to helping you gain access to HAEGARDA by offering personalized services. See all the support HAEGARDA Connect^SM offers such as financial assistance programs and self-administration training.

Learn More

Keep HAE attacks from getting in your way.

Because how you spend your days matters, the right therapy matters.
Ask your doctor about the HAEGARDA difference.

DISCOVER ALL THINGS HAEGARDA

Connect with us on Facebook

Important Safety Information

HAEGARDA^®, C1 Esterase Inhibitor Subcutaneous (Human), is an injectable medicine used to prevent swelling and/or painful attacks in patients 6 years of age and older with Hereditary Angioedema (HAE).

A healthcare professional can teach you (or caregiver) to self-administer HAEGARDA for prophylaxis. Do not use HAEGARDA to treat an acute HAE attack once it starts; work with your physician to plan for attacks if they occur.

Do not use HAEGARDA if you have previously experienced life-threatening immediate hypersensitivity reactions, such as shock, to HAEGARDA or other C1-INH products.

Immediately report any symptoms of allergic reactions to HAEGARDA, including hives, chest tightness, wheezing, difficulty breathing, turning blue, faintness, facial swelling and fast heartbeat.

Before starting HAEGARDA, tell your healthcare provider about all medical conditions you have—including pregnancy or nursing; a history of heart disease or stroke; an indwelling catheter/access device in a vein; or immobilization for a sustained period. Also tell your physician about any other medications you are taking, as some medications, such as birth control pills and certain androgens, can increase risk of clotting problems. High doses of C1-INH have been known to increase the risk of blood clots.

Immediately report to your physician or an emergency room if you have any of the following symptoms of a blood clot: pain or swelling of arm or leg, with warmth or discoloration over the affected area; unexplained shortness of breath; chest pain or discomfort that worsens on deep breathing; rapid pulse; and numbness or weakness on one side of the body.

In clinical studies, the most common side effects reported with HAEGARDA were injection-site reactions (pain, redness, swelling); hypersensitivity (itching and rash), dizziness, and nasal symptoms, including stuffy or runny nose and sneezing. These are not the only side effects possible with HAEGARDA. Tell your healthcare provider about any side effect that bothers you or does not go away.

Because HAEGARDA is made from human blood, the risk that it may transmit infectious agents, including viruses and theoretically, the agents of Creutzfeldt-Jakob Disease (CJD) and its variant form (vCJD), cannot be completely eliminated.

Please see full prescribing information for HAEGARDA, including patient product information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

You can also report side effects to CSL Behring’s Pharmacovigilance Department at 1-866-915-6958.

This email has been sent to you because we believe this information may be of value to you. If you no longer wish to receive these email communications, you may unsubscribe at any time.

View in a web browser

HAEGARDA is manufactured by CSL Behring GmbH and distributed by CSL Behring LLC.
HAEGARDA^® is a registered trademark of CSL Behring GmbH.
HAEGARDA Connect^SM is a service mark of CSL Behring LLC.
Biotherapies for Life^® is a registered trademark of CSL Behring LLC.
©2020 CSL Behring LLC.

1020 First Avenue, PO Box 61501, King of Prussia, PA 19406-0901 USA
www.CSLBehring.com www.haegarda.com HGD-1004-OCT20

TREAT YOUR DISEASE—
NOT JUST YOUR SYMPTOMS
WITH HAEGARDA

Discover the #1 prescribed
C1-INH therapy, addressing
the root cause of HAE

Please see Important Safety Information below

In clinical studies, the most common side effects reported with HAEGARDA were injection-site reactions (pain, redness, swelling); hypersensitivity (itching and rash), dizziness, and nasal symptoms, including stuffy or runny nose and sneezing.

HAEGARDA treats the primary cause of HAE,
not just the symptoms of an attack.

HAE attacks can occur when your levels of C1-inhibitor (C1-INH)—a key
protein in your body that controls swelling are too low or non-functioning.
HAEGARDA brings your working C1-INH levels back up and closer to
normal, reducing your risk of an HAE attack.

#1 PRESCRIBED

HAEGARDA is the #1 prescribed C1-INH preventive
therapy addressing HAE at its root cause.

Having a therapy that
addresses the root cause of
HAE is important to me. It''s
like filling in the missing
puzzle piece of C1-INH
my body doesn''t make.”

- Cheryl F, HAEGARDA Advocate*

HAE attacks can occur when your levels of working
C1-INH are too low

HAEGARDA brings your working C1-INH levels
back up and closer to normal, reducing your risk of an HAE attack

HAEGARDA is the #1 prescribed C1-INH therapy in
the US for the prevention of HAE attacks.

Ready to talk to your doctor about HAEGARDA?

You should always have HAE rescue medication available at all times in case of a breakthrough attack.

*	Advocates are not healthcare providers or medical experts, and are compensated for their participation. For medical questions, you should contact your physician.

	Median reduction in number of attacks in patients receiving 60 IU/kg of HAEGARDA vs placebo.

	Median reduction in rescue medication use in patients receiving 60 IU/kg of HAEGARDA vs placebo.

Important Safety Information

HAEGARDA^®, C1 Esterase Inhibitor Subcutaneous (Human), is an injectable medicine used to prevent swelling and/or painful attacks in patients 6 years of age and older with Hereditary Angioedema (HAE).

A healthcare professional can teach you (or caregiver) to self-administer HAEGARDA for prophylaxis. Do not use HAEGARDA to treat an acute HAE attack once it starts; work with your physician to plan for attacks if they occur.

Do not use HAEGARDA if you have previously experienced life-threatening immediate hypersensitivity reactions, such as shock, to HAEGARDA or other C1-INH products.

Immediately report any symptoms of allergic reactions to HAEGARDA, including hives, chest tightness, wheezing, difficulty breathing, turning blue, faintness, facial swelling and fast heartbeat.

Before starting HAEGARDA, tell your healthcare provider about all medical conditions you have–including pregnancy or nursing; a history of heart disease or stroke; an indwelling catheter/access device in a vein; or immobilization for a sustained period. Also tell your physician about any other medications you are taking, as some medications, such as birth control pills and certain androgens, can increase risk of clotting problems. High doses of C1-INH have been known to increase the risk of blood clots.

Immediately report to your physician or an emergency room if you have any of the following symptoms of a blood clot: pain or swelling of arm or leg, with warmth or discoloration over the affected area; unexplained shortness of breath; chest pain or discomfort that worsens on deep breathing; rapid pulse; and numbness or weakness on one side of the body.

In clinical studies, the most common side effects reported with HAEGARDA were injection-site reactions (pain, redness, swelling); hypersensitivity (itching and rash), dizziness, and nasal symptoms, including stuffy or runny nose and sneezing. These are not the only side effects possible with HAEGARDA. Tell your healthcare provider about any side effect that bothers you or does not go away.

Because HAEGARDA is made from human blood, the risk that it may transmit infectious agents, including viruses and theoretically, the agents of Creutzfeldt-Jakob Disease (CJD) and its variant form (vCJD), cannot be completely eliminated.

Please see full prescribing information for HAEGARDA, including patient product information.

You are encouraged to report negative side effects of prescription drugs to the FDA.
Visit www.fda.gov/medwatch, or call 1‑800‑FDA‑1088.

You can also report side effects to CSL Behring''s Pharmacovigilance Department at
1‑866‑915‑6958.

This email has been sent to you because we believe this information may be of value to you. If you no longer wish to receive these email communications, you may unsubscribe at any time.

View in a web browser

HAEGARDA is manufactured by CSL Behring GmbH and distributed by CSL Behring LLC.
HAEGARDA^® is a registered trademark of CSL Behring GmbH.
HAEGARDA Connect^SM is a service mark of CSL Behring LLC.
Biotherapies for Life^® is a registered trademark of CSL Behring LLC.

1020 First Avenue, PO Box 61501, King of Prussia, PA 19406-0901 USA

www.CSLBehring.com HGD-1002-SEP20

Treat Your Disease With C1-INH Therapy That Also Fits Into Your Routine

DISCOVER THE #1 PRESCRIBED C1‑INH THERAPY THAT ADDRESSES THE ROOT CAUSE OF HAE

The root cause of hereditary angioedema (HAE) is missing or nonworking C1 inhibitor (C1-INH), a key protein in your body that controls swelling. HAEGARDA adds functioning C1-INH to your body. Because of its dosing and subcutaneous delivery, HAEGARDA helps your working C1-INH levels stay high enough between doses to reduce the risk of an HAE attack from happening in the first place.

Please see Important Safety Information below.

In clinical studies, the most common side effects reported with HAEGARDA were injection-site reactions (pain, redness, swelling); hypersensitivity (itching and rash), dizziness, and nasal symptoms, including stuffy or runny nose and sneezing. These are not the only side effects possible with HAEGARDA. Tell your healthcare provider about any side effect that bothers you or does not go away.

HAEGARDA IS THE #1 PRESCRIBED THERAPY IN THE US FOR THE PREVENTION OF HAE ATTACKS

US OF RESCUE MEDICATION NEARLY ELIMINATED BY 100%

As a preventive therapy, HAEGARDA can effectively reduce the number of HAE attacks you experience. In a clinical study, HAEGARDA reduced HAE attacks by 95%.

^*Median reduction in number of attacks vs placebo.

^†Median reduction in rescue medication use vs placebo.

You should always have HAE rescue medication available at all times in case of a breakthrough attack.

READY TO TALK TO YOUR DOCTOR ABOUT HAEGARDA?

Important Safety Information

HAEGARDA^®, C1 Esterase Inhibitor Subcutaneous (Human), is an injectable medicine used to prevent swelling and/or painful attacks in adults and adolescents with hereditary angioedema (HAE).

A healthcare professional can teach you to self-administer HAEGARDA for prophylaxis. Do not use HAEGARDA to treat an acute HAE attack once it starts; work with your physician to plan for attacks if they occur.

Do not use HAEGARDA if you have previously experienced life-threatening immediate hypersensitivity reactions, such as shock, to HAEGARDA or other C1-INH products.

Immediately report any symptoms of allergic reactions to HAEGARDA, including hives, chest tightness, wheezing, difficulty breathing, turning blue, faintness, facial swelling and fast heartbeat.

Before starting HAEGARDA, tell your healthcare provider about all medical conditions you have-including pregnancy or nursing; a history of heart disease or stroke; an indwelling catheter/access device in a vein; or immobilization for a sustained period. Also tell your physician about any other medications you are taking, as some medications, such as birth control pills and certain androgens, can increase risk of clotting problems. High doses of C1-INH have been known to increase the risk of blood clots.

Immediately report to your physician or an emergency room if you have any of the following symptoms of a blood clot: pain or swelling of arm or leg, with warmth or discoloration over the affected area; unexplained shortness of breath; chest pain or discomfort that worsens on deep breathing; rapid pulse; and numbness or weakness on one side of the body.

In clinical studies, the most common side effects reported with HAEGARDA were injection-site reactions (pain, redness, swelling); hypersensitivity (itching and rash), dizziness, and nasal symptoms, including stuffy or runny nose and sneezing. These are not the only side effects possible with HAEGARDA. Tell your healthcare provider about any side effect that bothers you or does not go away.

Because HAEGARDA is made from human blood, the risk that it may transmit infectious agents, including viruses and theoretically, the agents of Creutzfeldt-Jakob Disease (CJD) and its variant form (vCJD), cannot be completely eliminated.

Please see prescribing information for HAEGARDA, including the patient product information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

This email has been sent to you because we believe this information may be of value to you. If you no longer wish to receive these email communications, you may unsubscribe at any time.

View in a web browser

HAEGARDA is manufactured by CSL Behring GmbH and distributed by CSL Behring LLC. HAEGARDA^® is a registered trademark of CSL Behring GmbH. HAEGARDA Connect^SM is a service mark of CSL Behring LLC. Biotherapies for Life^® is a registered trademark of CSL Behring LLC.

www.CSLBehring.com www.HAEGARDA.com HGD-0637-MAY19

Contact Us

|

Privacy Policy

|

Terms of Use

We appreciate your commitment!

Dear Charlotte,

Thank you for signing up to receive the latest information and updates for HAEGARDA, the only C1-INH subcutaneous injection for the prevention of HAE attacks.

You''ll begin to receive information shortly. To learn more now, visit us at
www.HAEGARDA.com.

Important Safety Information

A healthcare professional can teach you to self-administer HAEGARDA^®, C1 Esterase Inhibitor Subcutaneous (Human), for prophylaxis. Do not use HAEGARDA to treat an acute HAE attack once it starts; work with your physician to plan for attacks if they occur.

Do not use HAEGARDA if you have previously experienced life-threatening immediate hypersensitivity reactions, such as shock, to HAEGARDA or other C1-INH products. Immediately report any symptoms of allergic reactions to HAEGARDA, including hives, chest tightness, wheezing, difficulty breathing, turning blue, faintness, facial swelling and fast heartbeat.

Before starting HAEGARDA, tell your healthcare provider about all medical conditions you have-including pregnancy or nursing; a history of heart disease or stroke; an indwelling catheter/access device in a vein; or immobilization for a sustained period. Also tell your physician about any other medications you are taking, as some medications, such as birth control pills and certain androgens, can increase risk of clotting problems. High doses of C1-INH have been known to increase the risk of blood clots.

Immediately report to your physician or an emergency room if you have any of the following symptoms of a blood clot: pain or swelling of arm or leg, with warmth or discoloration over the affected area; unexplained shortness of breath; chest pain or discomfort that worsens on deep breathing; rapid pulse; and numbness or weakness on one side of the body.

In clinical studies, the most common side effects reported with HAEGARDA were injection-site reactions (pain, redness, swelling); hypersensitivity (itching and rash), dizziness, and nasal symptoms, including stuffy or runny nose and sneezing. These are not the only side effects possible with HAEGARDA. Tell your healthcare provider about any side effect that bothers you or does not go away.

Because HAEGARDA is made from human blood, the risk that it may transmit infectious agents, including viruses and theoretically, the agents of Creutzfeldt-Jakob Disease (CJD) and its variant form (vCJD), cannot be completely eliminated.

HAEGARDA is an injectable medicine used to prevent swelling and/or painful attacks in adults and adolescents with hereditary angioedema (HAE).

Please see full prescribing information for HAEGARDA, including the patient product information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

If you no longer wish to receive these e-mail communications you may unsubscribe at any time.

View in a web browser

HAEGARDA is manufactured by CSL Behring GmbH and distributed by CSL Behring LLC. HAEGARDA is a registered trademark of CSL Behring GmbH.

©2019 CSL Behring LLC 1020 First Avenue, PO Box 61501, King of Prussia PA 19406-0901 USA www.CSLBehring.com www.HAEGARDA.com HGD-0591-FEB19

Contact Us

|

Privacy Policy

|

Terms of Use

With HAEGARDA, Picture the Possibility of Only 1 Attack Per Year*

Stop letting hereditary angioedema (HAE) interrupt your life. HAEGARDA is the only subcutaneous C1-INH preventive therapy. If you experience frequent attacks, or if attacks are making it hard to go about your daily life, HAEGARDA may be able to help you.

*Median attack rate in patients followed over an average of 1.5 years.

READY TO TALK TO YOUR DOCTOR ABOUT SWITCHING TO HAEGARDA?

Please see Important Safety Information below.

In clinical studies, the most common side effects reported with HAEGARDA were injection-site reactions (pain, redness, swelling); hypersensitivity (itching and rash), dizziness, and nasal symptoms, including stuffy or runny nose and sneezing. These are not the only side effects possible with HAEGARDA. Tell your healthcare provider about any side effect that bothers you or does not go away.

HAEGARDA IS THE #1 PRESCRIBED THERAPY IN THE US FOR THE PREVENTION OF HAE ATTACKS

USE OF RESCUE MEDICATION NEARLY ELIMINATED BY 100%

As a preventive therapy, HAEGARDA can effectively reduce the number of HAE attacks you experience. In a clinical study, HAEGARDA reduced HAE attacks by 95%.

^†Median reduction in number of attacks vs placebo.

^‡Median reduction in rescue medication use vs placebo.

You should always have HAE rescue medication available at all times in case of a breakthrough attack.